Application of anti-GSDMD autoantibody in preparation of product for diagnosing lung adenocarcinoma
Through the combined detection of anti-GSDMD autoantibodies and traditional tumor markers, the problem of insufficient specificity and sensitivity in early diagnosis of lung cancer is solved, and an efficient minimally invasive diagnosis method is provided, which significantly improves the diagnostic accuracy of lung adenocarcinoma.
Patent Information
- Application Number
- CN202411078798.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-06
AI Technical Summary
The prior art lacks high specificity and high sensitivity methods in the early diagnosis of lung cancer. The high false positive rate and radiation risk of imaging examinations and serological marker detection lead to insufficient early screening of lung cancer.
Anti-GSDMD autoantibodies are used as plasma biomarkers, combined with traditional tumor markers CEA, CA199, AFP, and CA125 for logistic regression testing, and plasma samples of lung adenocarcinoma patients were detected through ELISA, providing diagnostic reagents for lung adenocarcinoma and Reagent test kit.
It significantly improves the diagnostic efficacy of lung adenocarcinoma, can effectively distinguish patients with lung adenocarcinoma from healthy controls and benign lung nodules, and provides a highly specific, high-accurate minimally invasive diagnosis method with broad market prospects and society. benefit.
Smart Images

Figure CN119001101A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to use of anti-GSDMD autoantibodies in preparing lung adenocarcinoma (LUAD) auxiliary diagnosis products. Background Art
[0002] This section merely provides background information related to the present disclosure and is not necessarily prior art.
[0003] Lung cancer (LC) is a major public health problem, causing a large number of deaths worldwide. The 2020 estimates of GLOBOCAN (Global Cancer Observatory) on cancer incidence and mortality by the International Agency for Research on Cancer (IARC) show that lung cancer remains the leading cause of cancer deaths, causing an estimated 1.8 million deaths (18%) in 2020. Lung cancer is mainly divided into two categories based on histopathology: small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer includes squamous cell carcinoma (SCC), adenocarcinoma, and large cell lung cancer. Lung cancer seriously threatens human health. Many studies in my country have shown that the incidence and mortality of lung cancer are constantly increasing. Lung cancer is the leading cause of morbidity and mortality from malignant tumors in China.
[0004] At present, conventional treatments for lung cancer include surgical resection, radiotherapy, chemotherapy, etc., but these treatments are not suitable for all lung cancer patients. Among various treatment methods, surgical treatment has the best effect, but only 20% to 30% of patients are clinically suitable for surgical treatment. Chemotherapy was the earliest and most widely used treatment method, and it is currently the most mature treatment method, but it has large clinical side effects and poor quality of life for patients. Radiotherapy is a local treatment method that is not effective for distant metastatic tumors and has similarly large side effects. Clinical studies have found that most lung cancer patients are already in the middle and late stages of lung cancer when diagnosed, and most of them do not have the opportunity for surgery, making treatment difficult and ineffective. Early lung cancer often has no obvious clinical symptoms and signs. Most lung cancer patients are already in the late stage when they first visit the doctor with symptoms. The 5-year survival rate of advanced lung cancer is extremely low. Therefore, exploring effective early diagnosis methods for lung cancer is of great significance for improving the survival prognosis of lung cancer patients.
[0005] Imaging and marker examinations are commonly used methods for early diagnosis of lung cancer. However, among the diagnostic methods currently used in clinical practice, imaging examinations lack specificity and can only be used as auxiliary diagnostic indicators; the sensitivity and specificity of serological tumor marker detection are low, and the diagnostic value is limited; low-dose spiral CT (LDCT) has a high false positive rate due to the structure, size, number, occurrence and development characteristics of lung nodules themselves and the principle of CT imaging, leading to overdiagnosis and treatment, and there is a radiation risk, which poses a threat to human health. It is insufficient for early screening of lung cancer, so it is necessary to actively explore more effective methods for early diagnosis of lung cancer.
[0006] Tumor-associated autoantibody spectrum detection or combined detection with tumor autoantigens have shown good specificity and sensitivity in the early screening and early diagnosis of lung cancer. After tumor cells appear in the human body, the body's immune system can produce a specific immune response to tumor-associated antigens (TAA) and produce a series of TAA autoantibodies. TAA autoantibodies can be detected in the early stages of lung cancer and can therefore be used as biomarkers for early diagnosis of lung cancer. In order to seek better diagnostic methods, high-specificity and high-accuracy lung cancer autoantibodies have become a hot topic of research. Summary of the invention
[0007] Purpose of the invention: The technical problem to be solved by the present invention is to provide the use of anti-GSDMD autoantibodies in the preparation of products for diagnosing lung adenocarcinoma in view of the deficiencies in the prior art.
[0008] In order to solve the above technical problems, the present invention discloses the following technical solutions:
[0009] In a first aspect, the present invention discloses a plasma biomarker for diagnosing lung adenocarcinoma.
[0010] Wherein, the diagnostic marker for lung adenocarcinoma includes anti-GSDMD autoantibodies.
[0011] The present invention firstly finds that the expression level of anti-GSDMD IgG autoantibodies in the plasma of patients with lung adenocarcinoma is significantly higher than that of healthy controls and patients with benign lung nodules, and the difference is significant.
[0012] In a second aspect, the present invention discloses a reagent for diagnosing lung adenocarcinoma.
[0013] Wherein, the lung adenocarcinoma marker includes anti-GSDMD autoantibodies.
[0014] Wherein, the autoantibody is an IgG type autoantibody.
[0015] Wherein, the autoantibodies are autoantibodies in peripheral blood plasma.
[0016] Furthermore, the product also includes serum tumor markers.
[0017] The serum tumor markers include traditional tumor markers CEA, CA199, AFP, CA125, or any combination of the foregoing. The present invention uses Logistic regression to jointly detect GSDMD IgG autoantibodies with traditional tumor markers CEA, CA199, AFP and CA125 and finds that the combined diagnostic efficacy for lung adenocarcinoma is better than using the above markers alone.
[0018] Wherein, the diagnosis of lung adenocarcinoma includes detecting autoantibodies by ELISA; further, it also includes detecting the expression level of traditional tumor markers CEA, CA199, AFP, CA125, or any combination of the foregoing.
[0019] In a third aspect, the present invention discloses use of the diagnostic lung adenocarcinoma marker described in the first aspect or the reagent described in the second aspect in the preparation of a product for diagnosing lung adenocarcinoma.
[0020] Wherein, the diagnosis of lung adenocarcinoma includes detecting autoantibodies by ELISA; further, it also includes detecting the expression level of traditional tumor markers CEA, CA199, AFP, CA125, or any combination of the foregoing.
[0021] In a fourth aspect, the present invention discloses a kit.
[0022] Wherein, the kit comprises the diagnostic marker for lung adenocarcinoma described in the first aspect or the reagent described in the second aspect.
[0023] Wherein, the kit is an ELISA detection kit.
[0024] Wherein, the kit comprises GSDMD protein.
[0025] The basic information of the tumor-associated antigen GSDMD in the present invention is: it is located on the eighth chromosome of humans, encodes 484 amino acids, and contains 14 exons. This protein is a very important target protein downstream of the classical and non-classical inflammatory response pathways. It will cause cell pyroptosis after being cleaved by caspase, and is a key molecule regulating cell inflammatory necrosis (cell pyroptosis). GSDMD contains a cytotoxic N-terminal domain and a C-terminal inhibitory domain, which are connected by a flexible component. After the connecting protein between the two domains is hydrolyzed, the intramolecular inhibition of the cytotoxic domain will be released, allowing the N-terminal domain to be inserted into the cell membrane to form a large oligomeric pore, thereby destroying the cell's ion homeostasis and inducing cell death. GSDMD-induced cell pyroptosis plays an important role in many genetic diseases, autoinflammatory diseases and cancers.
[0026] The method for screening lung adenocarcinoma markers described in the present invention specifically comprises the following steps: (1) collecting blood samples from lung adenocarcinoma patients, healthy people, and patients with benign lung nodules, and obtaining plasma samples after separation and treatment; (2) screening and identifying plasma protein markers in lung adenocarcinoma patients, healthy people, and patients with benign lung nodules.
[0027] The method for verifying lung adenocarcinoma markers described in the present invention is specifically to verify the differential plasma protein ELISA between lung adenocarcinoma patients, healthy people and benign lung nodule patients after screening and identifying the plasma protein markers of lung adenocarcinoma patients, healthy people and benign lung nodule patients in the aforementioned step (2).
[0028] The differential plasma protein ELISA verification includes: the optimal protein coating concentration of GSDMD and the optimal dilution concentration of the secondary antibody; performing ELISA testing on the plasma samples according to the instructions of the kit; and performing statistical analysis on the obtained data.
[0029] The biomarker for auxiliary diagnosis of lung adenocarcinoma provided by the present invention is an antibody
[0030] Gasdermin-D (GSDMD) autoantibodies were detected in the plasma of patients with lung adenocarcinoma, and the expression level of this marker was higher than that in patients with benign pulmonary nodules and healthy controls, and the difference was statistically significant.
[0031] The novel plasma anti-GSDMD provided by the present invention is combined with serum tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), alpha-fetoprotein (AFP), and carbohydrate antigen 125 (CA125), which has good efficacy in the differential diagnosis of lung adenocarcinoma and is of great significance for the management and identification of patients with lung adenocarcinoma.
[0032] The diagnosis of lung adenocarcinoma in the present invention includes distinguishing lung adenocarcinoma from healthy people, and / or distinguishing lung adenocarcinoma from benign lung nodules.
[0033] The diagnosis of lung adenocarcinoma in the present invention includes auxiliary diagnosis of lung adenocarcinoma.
[0034] In the present invention, serum CEA, CA199, CA125 and AFP are detected by electrochemiluminescence method, and the unit is ng / mL.
[0035] Beneficial effects:
[0036] The present invention screens and identifies novel plasma biomarkers (anti-GSDMD autoantibodies) that can be used for differential diagnosis of lung adenocarcinoma patients, healthy people, and benign pulmonary nodules patients through enzyme-linked immunosorbent assay. GSDMD is combined with tumor markers CEA, CA199, CA125, and AFP to construct a differential diagnosis model for lung adenocarcinoma patients, healthy people, and benign pulmonary nodules. The model has good differential diagnosis efficacy for lung adenocarcinoma patients, healthy people, and benign pulmonary nodules, and provides help for better clinical management of lung adenocarcinoma patients. The test sample of the kit of the present invention is plasma, which can avoid invasive diagnosis. The risk of lung adenocarcinoma can be obtained in the early stage by taking plasma for detection in a minimally invasive manner, requiring less blood, less pain for the person being tested, and high compliance; moreover, the operation is simple, the time to detect the result is short, and it has broad market prospects and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.
[0038] Figure 1 The SBI scatter plot and ROC curve of anti-GSDMD IgG autoantibodies in the training sample set in lung adenocarcinoma and healthy controls.
[0039] Figure 2To verify the SBI scatter plot and ROC curve of anti-GSDMD IgG autoantibodies in the sample set for diagnosing lung adenocarcinoma, benign pulmonary nodules and healthy controls.
[0040] Figure 3 The ROC curve of anti-GSDMD IgG autoantibodies combined with traditional tumor marker CEA in the diagnosis of lung adenocarcinoma, benign lung nodules and healthy controls.
[0041] Figure 4 The ROC of anti-GSDMD IgG autoantibodies combined with traditional tumor marker CA199 in the diagnosis of lung adenocarcinoma, benign lung nodules and healthy controls.
[0042] Figure 5 The ROC curve of anti-GSDMD IgG autoantibodies combined with the traditional tumor marker AFP in the diagnosis of lung adenocarcinoma, benign lung nodules and healthy controls.
[0043] Figure 6 The ROC of GSDMD IgG autoantibodies combined with traditional tumor marker CA125 for the diagnosis of lung adenocarcinoma, benign lung nodules and healthy controls. DETAILED DESCRIPTION
[0044] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.
[0045] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.
[0046] Example: ELISA to detect the plasma expression level of anti-GSDMD autoantibodies
[0047] 1. Experimental samples
[0048] This study included 136 training set samples, including 68 patients with lung adenocarcinoma and 68 healthy controls, and 900 validation set samples, including 309 patients with lung adenocarcinoma, 300 patients with benign pulmonary nodules, and 291 healthy people. All samples were collected from a tertiary hospital in Henan Province from November 2019 to May 2022. The basic information, pathological stage, and clinical traditional tumor marker levels of all subjects were summarized and organized through the hospital's internal system with the consent of the patients and the approval of the institutional review board and the hospital ethics committee. The basic information of the specific research subjects is shown in Tables 1 and 2.
[0049] Table 1 Basic characteristics of the research subjects of the training set samples
[0050]
[0051] Table 2 Basic characteristics of the validation set sample research subjects
[0052]
[0053] (1) Patient sample and information collection process
[0054] 1) For patients who were hospitalized for suspicious lung nodules detected by CT scans, blood samples were collected on the first day or the second day of hospitalization without receiving any treatment (blood samples were collected from some lung cancer patients after treatment), and the samples were numbered, packaged, and their basic information was registered before being included in the blood sample library.
[0055] 2) After the patient is diagnosed, the hospitalization number, gender, age and other information of the research subject are consulted in the hospital patient management system and relevant clinical information is collected, including the smoking history, drinking history, traditional tumor markers (detection values and cutoff values of CEA, CA199, AFP, CA125, etc.) of patients with lung adenocarcinoma and benign lung nodules, and a patient clinical information database is established.
[0056] (2) Healthy control samples and information collection process
[0057] The data were collected from people who had physical examinations in a tertiary hospital in Henan Province. The physical examination number, gender, age and other information of the research subjects were consulted in the hospital patient management system and relevant clinical information was collected. Their blood samples were collected, numbered, packaged, and registered in the blood sample data information database before being included in the blood sample library.
[0058] (3) Inclusion and exclusion criteria of research subjects
[0059] The inclusion criteria for patients with lung adenocarcinoma included: 1) no chemotherapy, radiotherapy, surgery, or other interventions; 2) clear histopathological results, confirmed as lung adenocarcinoma according to the guidelines for the diagnosis and treatment of primary lung cancer, and pathological histological types (including adenocarcinoma, carcinoma, adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, and mixed carcinoma); 3) no history of other malignant tumors; 4) complete medical history; 5) no autoimmune diseases; 6) all were new cases; 7) patients were aged ≥18 years.
[0060] The inclusion criteria for patients with benign pulmonary nodules included: 1) clear histopathological biopsy to confirm the benign or malignant status and pathological histological type; 2) no history of malignant tumors in the lung or other parts of the body; 3) all were new cases without any treatment; 4) age >18 years old.
[0061] The inclusion criteria for healthy controls included: 1) no history of malignant tumors in the lung or other parts of the body; 2) no autoimmune diseases; 3) age >18 years old.
[0062] Exclusion criteria: subjects who do not meet the above inclusion criteria.
[0063] (4) Plasma collection:
[0064] 5 ml of peripheral blood was collected from the subjects in a fasting state and placed in a blood collection tube without anticoagulant. After standing at room temperature for 1 hour, it was placed in a centrifuge set at 4°C and centrifuged at 3000 rpm for 10 minutes. The serum on the upper layer of the blood collection tube was then aspirated and dispensed into 1.5 ml EP tubes. The sample number was marked on the top and side of the EP tubes and placed in a -80°C refrigerator for frozen storage. The blood collection date and storage location were recorded. Before use, the plasma was taken out and thawed in a 4°C refrigerator and dispensed to avoid repeated freezing and thawing of the plasma.
[0065] 2. Experimental Materials and Reagents
[0066] (1) GSDMD protein was purchased from Wuhan Cloud-Clone Technology Service Co., Ltd.;
[0067] (2) 96-well ELISA plate (8 rows × 12 columns);
[0068] (3) Coating solution: an aqueous solution containing 0.15% sodium carbonate (Na2CO3) and 0.29% sodium bicarbonate (NaHCO3);
[0069] (4) Blocking solution: PBST buffer containing 2% (v / v) bovine serum albumin (BSA) and 0.2% (v / v) Tween 20;
[0070] (5) Plasma sample diluent: PBST buffer containing 1% (W / V) BSA;
[0071] (6) Enzyme-labeled secondary antibody: recombinant protein A labeled with horseradish peroxidase (HRP);
[0072] (7) Antibody diluent: PBST buffer containing 1% (w / v) BSA;
[0073] (8) Washing solution: PBST buffer containing 0.2% (v / v) Tween 20;
[0074] (9) Colorimetric solution: The colorimetric solution consists of colorimetric solution A and colorimetric solution B, wherein colorimetric solution A is an aqueous solution of 20% tetramethylbenzidine dihydrochloride, and colorimetric solution B is an aqueous solution containing 3.7% Na2HPO4·12H2O, 0.92% citric acid and 0.75% (v / v) urea hydrogen peroxide; when in use, colorimetric solution A and colorimetric solution B are mixed evenly in equal volumes of 1:1 and prepared before use; (10) Quality control plasma: 100 normal control blood samples are fully mixed in equal amounts to prepare quality control blood samples for quality control (Quality control, QC), which is used to eliminate the errors between various ELISA plates and represent the general level of the population. If the CV of quality control samples between all ELISA plates made on the same day is less than 20%, the data can be used for subsequent analysis;
[0075] (11) Stop solution: 10% sulfuric acid.
[0076] 3. Experimental methods
[0077] (1) Protein pretreatment and determination of protein concentration: Use the protein diluent recommended in the protein manual to dilute the protein to an appropriate concentration and then perform SDS-PAGE electrophoresis to confirm the protein concentration.
[0078] (2) Preliminary experiments explored the optimal protein coating concentration of GSDMD and the dilution concentration of secondary antibody IgG: Plasma from four patients with lung adenocarcinoma and four healthy controls was randomly selected for the preliminary experiment. Two concentration gradients were set for the protein coating concentration and the dilution concentration of the secondary antibody. After the experiment, the optimal multiple was selected based on the sample OD value and the standard OD value to ensure that the color development time of the sample and the standard was consistent and that the sample OD value was between the highest and lowest OD values of the standard.
[0079] (3) Training set sample experiment: After determining the optimal protein coating concentration of GSDMD and the dilution concentration of the secondary antibody IgG, plasma from lung adenocarcinoma patients and healthy controls were randomly selected for a small sample experiment. Among them, there were 68 lung adenocarcinoma patients and 68 healthy controls.
[0080] (4) Validation set sample experiment: Plasma from patients with lung adenocarcinoma, benign lung nodules, and healthy controls was randomly selected for a large sample experiment, including 309 patients with lung adenocarcinoma, 291 healthy controls, and 300 patients with benign lung nodules.
[0081] (5) Plate layout: According to the layout of the 96-well ELISA plate, calculate the number of samples, sample volume, protein volume, sample layout, etc. in advance. Calculate the total amount of reagents required for subsequent use based on the sample volume and prepare them in advance. The blank well is 1% BSA, and the sample volume is 50 μL / well. The sample layout table is shown in Tables 3 and 4.
[0082] Table 3 Training set sample layout table (taking the first board as an example)
[0083] NCl NC2 NC3 NC4 NC5 NC6 NC7 NC8 NC9 NC10 NC11 Quality Control NC12 NC13 NC14 NC15 NC16 NC17 NC18 NC19 NC20 NC21 NC22 Quality Control NC23 NC24 NC25 NC26 NC27 NC28 NC29 NC30 NC31 NC32 NC33 blank NC34 NC35 NC36 NC37 NC 38 NC 39 NC 40 NC 41 NC 42 NC 43 NC 44 blank LC4 LC48 LC104 LC165 LC200 LC230 LC254 LC332 LC373 LC439 LC464 blank LC6 LC59 LC107 LC174 LC204 LC231 LC269 LC337 LC376 LC446 LC474 blank LC9 LC72 LC120 LC175 LC205 LC238 LC272 LC341 LC378 LC449 LC478 blank LC13 LC80 LC122 LC177 LC206 LC239 LC283 LC348 LC380 LC450 LC486 blank
[0084] Table 4 Validation set sample layout table (taking the first board as an example)
[0085] LC1 LC2 LC4 LC5 LC7 LC8 LC11 LC12 LC15 LC16 LC18 Quality Control LC19 LC20 LC21 LC22 LC23 LC24 LC25 LC27 LC28 LC29 LC30 Quality Control LC36 LC38 LC39 LC40 LC41 LC42 LC44 LC45 LC46 LC47 LC48 blank BPN1 BPN2 BPN3 BPN4 BPN5 BPN6 BPN7 BPN8 BPN9 BPN10 BPN11 blank BPN12 BPN13 BPN14 BPN15 BPN16 BPN17 BPN18 BPN19 BPN20 BPN21 BPN22 blank NC1 NC2 NC3 NC4 NC5 NC6 NC7 NC8 NC9 NC10 NC11 blank NC12 NC13 NC14 NC15 NC16 NC17 NC18 NC19 NC20 NC21 NC22 blank NC23 NC24 NC25 NC26 NC27 NC28 NC29 NC30 NC31 NC32 NC33 blank
[0086] (6) Sample subpackaging and sample dilution: After selecting the required experimental samples from the sample library, slowly thaw them in a 4°C refrigerator the day before the experiment. The next day, the samples are divided into 96-well pointed-bottom PCR plates according to the previous layout and the required sample volume. Then, according to the sample dilution ratio required for the experiment, the samples are added to the antibody diluent in the corresponding layout of the 96-well deep-well plate, and the surface is covered with a film for sealing, and then placed in a 4°C refrigerator for future use.
[0087] (7) Protein coating: Use coating solution to dilute the protein to the optimal coating concentration (0.125 μg / mL) determined in the preliminary experiment. After shaking, add the prepared GSDMD protein solution to the reaction wells in columns 1 to 12 of a 96-well ELISA plate at a volume of 50 μL / well. Cover with plastic wrap to prevent evaporation and coat overnight at 4°C.
[0088] (8) Blocking: Add blocking solution to each reaction well of the coated 96-well ELISA plate at a volume of 100 μL / well, and block in a 37°C water bath for 2 h. Then remove the blocking solution, wash three times with washing solution and pat dry to obtain an ELISA plate coated with the tumor-associated antigen GSDMD.
[0089] (9) Primary antibody (plasma) reaction: The plasma sample to be tested was diluted with plasma sample diluent at a volume ratio of 1:100, and then the diluted plasma sample was added to the ELISA plate according to the layout of the plate at a specification of 50 μL / well, and the sample volume was 50 μL / well; 50 μL / well of antibody diluent (without any plasma sample) was also added to the blank wells. Then the 96-well ELISA plate was placed in a 37°C water bath for incubation for 1 hour, and then the liquid in the reaction wells was discarded, and the wells were washed 5 times with washing solution (the sample volume was 300 μL / well) and patted dry.
[0090] (10) Enzyme-labeled secondary antibody incubation: For the secondary antibody reaction, HRP-labeled recombinant protein A was diluted with antibody diluent at a ratio of 1:5000 (v / v) determined in the preliminary experiment. The diluted HRP-labeled recombinant protein A was then added to each reaction well of a 96-well ELISA plate at a volume of 50 μl / well. The plates were incubated in a 37°C water bath for 1 h. The liquid in the reaction wells was then discarded, and the plates were washed five times with washing solution (300 μl / well) and patted dry.
[0091] (11) Color development and termination reaction: Color development solution A and color development solution B were mixed in a 1:1 ratio of equal volumes, and then the mixed color development solution was quickly added to the reaction wells of the 96-well ELISA plate at a volume of 50 μl / well. The mixture was kept at room temperature and away from light. The color development was observed at all times during the color development process. After sufficient color development, 25 μl of stop solution was added to each reaction well to terminate the color development reaction. The absorbance (optical density, OD) at 450 nm and 620 nm was then read using an ELISA reader. The absorbance at 620 nm was the background value. The difference between the absorbance at 450 nm and 620 nm was used as the absorbance value for subsequent analysis, and the blank control well was used for zero adjustment.
[0092] 4. Data processing
[0093] The statistical analysis method of the present invention is to use SPSS26.0, GraphPad Prism 8.0 software to perform statistical analysis on the experimental data and visualize the results. The difference in the expression level of anti-GSDMD autoantibodies between different groups was analyzed by Mann-Whitney U test, and the difference in positive rate was analyzed by chi-square test; the SBI value corresponding to the maximum Youden's Index (YI) was taken as the cutoff value, and the diagnostic value indicators such as AUC, specificity, sensitivity and 95% confidence interval (95% CI) of anti-GSDMD autoantibodies were calculated by ROC curve. All statistical analyses were performed using two-sided tests, and when P<0.05, the difference was considered statistically significant.
[0094] 5. Results Analysis
[0095] (1) ELISA preliminary experiment to explore the optimal protein coating concentration of GSDMD and the optimal dilution concentration of secondary antibody IgG: A double antibody sandwich ELISA experiment was used to conduct a preliminary analysis of a small number of samples (plasma from 4 patients with lung adenocarcinoma and 4 patients with benign lung nodules) to explore the optimal protein coating concentration of GSDMD and the optimal dilution concentration of secondary antibody IgG in this experiment. The optimal protein coating concentration of GSDMD and the optimal dilution multiple of secondary antibody IgG are shown in Table 5.
[0096] Table 5 ELISA preliminary experiment to explore the optimal protein coating concentration of GSDMD and the optimal dilution multiple of secondary antibody IgG
[0097]
[0098] (2) Preliminary verification of the differential diagnostic efficacy of IgG autoantibodies against GSDMD by ELISA
[0099] The expression levels of anti-GSDMD IgG autoantibodies in the plasma samples of lung adenocarcinoma group and healthy control group are as follows Figure 1 As shown in the figure, the expression level of anti-GSDMD autoantibodies in the plasma samples of the lung adenocarcinoma group was significantly higher than that of the healthy control group (P<0.0001).
[0100] The expression levels of anti-GSDMD IgG autoantibodies in the plasma samples of lung adenocarcinoma group, healthy control group and benign pulmonary nodule group are shown in Figure 2 Figure 2 As shown in the figure, the expression level of anti-GSDMD autoantibodies in the plasma samples of the lung adenocarcinoma group was significantly higher than that of the healthy control group (P<0.0001) and the benign lung nodule group (P<0.0001). Figure 2 It can be seen that the receiver operating characteristic (ROC) curve analysis showed that when anti-GSDMD IgG autoantibodies were used to diagnose and distinguish between lung adenocarcinoma and healthy control groups, the AUC of the ROC curve was 0.77 (95% CI: 0.73-0.80), and when the cutoff value was 0.60, the sensitivity of anti-GSDMD IgG autoantibodies to diagnose and distinguish between lung adenocarcinoma and healthy control groups reached 78%, and the specificity reached 65%; and the area under the curve of anti-GSDMD IgG autoantibodies to diagnose and distinguish between lung adenocarcinoma and benign pulmonary nodule groups was 0.66 (95% CI: 0.61-0.70), and when the cutoff value was 0.60, the sensitivity reached 78%, and the specificity reached 54%. This shows that anti-GSDMD IgG autoantibodies can distinguish lung adenocarcinoma from healthy control groups and benign pulmonary nodule groups. This also proves that anti-GSDMD autoantibodies can be used for auxiliary diagnosis of lung adenocarcinoma.
[0101] Figure 3 Logistic regression was used to detect anti-GSDMD IgG autoantibodies and traditional tumor markers CEA. The AUC of the ROC curve for distinguishing between lung adenocarcinoma and healthy controls was 0.80 (95% CI: 0.70-0.85), which was higher than the area under the curve of CEA alone for distinguishing between lung adenocarcinoma and healthy controls, which was 0.55 (95% CI: 0.48-0.63); the AUC of the ROC curve for distinguishing between lung adenocarcinoma and benign pulmonary nodules was 0.64 (95% CI: 0.56-0.71), which was also higher than the area under the curve of CEA alone for distinguishing between lung adenocarcinoma and benign pulmonary nodules, which was 0.60 (95% CI: 0.53-0.68). A total of 451 cases were included in the lung adenocarcinoma group (LUAD), healthy controls (NC), and benign pulmonary nodules (BPN).
[0102] Figure 4Logistic regression was used to detect anti-GSDMD IgG autoantibodies and traditional tumor marker CA199. The AUC of the ROC curve for distinguishing lung adenocarcinoma from healthy controls was 0.73 (95% CI: 0.65-0.81), which was higher than the area under the curve of CA199 alone for distinguishing lung adenocarcinoma from healthy controls (0.51 (95% CI: 0.42-0.61); the AUC of the ROC curve for distinguishing lung adenocarcinoma from benign pulmonary nodules was 0.68 (95% CI: 0.60-0.75), which was also higher than the area under the curve of CA199 alone for distinguishing lung adenocarcinoma from benign pulmonary nodules (0.50 (95% CI: 0.42-0.59). A total of 238 cases were included in the lung adenocarcinoma group (LUAD), healthy controls (NC), and benign pulmonary nodules (BPN).
[0103] Figure 5 Logistic regression was used to detect anti-GSDMD IgG autoantibodies and traditional tumor marker AFP. The AUC of the ROC curve for distinguishing lung adenocarcinoma from healthy controls was 0.77 (95% CI: 0.71-0.83), which was higher than the area under the curve of AFP alone for distinguishing lung adenocarcinoma from healthy controls (0.52 (95% CI: 0.45-0.60); the AUC of the ROC curve for distinguishing lung adenocarcinoma from benign pulmonary nodules was 0.69 (95% CI: 0.61-0.77), which was also higher than the area under the curve of AFP alone for distinguishing lung adenocarcinoma from benign pulmonary nodules (0.54 (95% CI: 0.45-0.62). A total of 354 cases were included in the lung adenocarcinoma group (LUAD), healthy controls (NC), and benign pulmonary nodules (BPN).
[0104] Figure 6 The IgG autoantibodies against GSDMD and the traditional tumor marker CA125 were detected by L1gistic regression. The AUC of the ROC curve for distinguishing the lung adenocarcinoma group from the healthy control group was 0.80 (95% CI: 0.73-0.88), which was higher than the area under the curve of CA125 alone for distinguishing the lung adenocarcinoma group from the healthy control group (0.62 (95% CI: 0.52-0.71); the AUC of the ROC curve for distinguishing the lung adenocarcinoma group from the benign pulmonary nodule group was 0.62 (95% CI: 0.55-0.69), which was also higher than the area under the curve of CA125 alone for distinguishing the lung adenocarcinoma group from the benign pulmonary nodule group (0.54 (95% CI: 0.46-0.61). A total of 280 cases were included in the lung adenocarcinoma group (LUAD), the healthy control group (NC), and the benign pulmonary nodule group (BPN).
[0105] Table 6 AUC of GSDMD autoantibodies combined with other tumor markers
[0106]
[0107] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A reagent for diagnosing lung adenocarcinoma, characterized in that The lung adenocarcinoma markers include anti-GSDMD autoantibodies.
2. The reagent according to claim 1, characterized in that The autoantibodies are IgG type autoantibodies.
3. The reagent according to claim 1, characterized in that The autoantibodies are autoantibodies in plasma.
4. The reagent according to claim 1, characterized in that The product also includes serum tumor markers; preferably, the serum tumor markers include traditional tumor markers CEA, CA199, AFP, CA125, or a combination of any of the foregoing.
5. The reagent according to claim 1, characterized in that The diagnosis of lung adenocarcinoma includes distinguishing lung adenocarcinoma from healthy people, and / or distinguishing lung adenocarcinoma from benign lung nodules.
6. The reagent according to claim 1, characterized in that The diagnosis of lung adenocarcinoma includes detecting autoantibodies by ELISA; preferably, it also includes detecting the expression level of traditional tumor markers CEA, CA199, AFP, CA125, or any combination of the foregoing.
7. Use of the reagent according to any one of claims 1 to 6 in the preparation of a product for diagnosing lung adenocarcinoma.
8. The use according to claim 7, characterized in that The diagnosis of lung adenocarcinoma includes distinguishing lung adenocarcinoma from healthy people, and / or distinguishing lung adenocarcinoma from benign lung nodules; Preferably, the diagnosis of lung adenocarcinoma includes detecting autoantibodies by ELISA; preferably, it also includes detecting the expression level of traditional tumor markers CEA, CA199, AFP, CA125, or a combination of any of the foregoing.
9. A kit, characterized in that: The invention comprises the reagent according to any one of claims 1 to 6.
10. The kit according to claim 9, characterized in that The kit is an ELISA detection kit; preferably, the kit comprises GSDMD protein.
Citation Information
Patent Citations
Lung non-cellule cancer early stage specific self antibody panel diagnostic kit
CN108333375A
